In chronic myeloid leukemia (CML) therapy with tyrosine kinase inhibitors (TKIs), genetic and pharmacological inhibition of ILK has been found to sensitize resistant leukemic stem cells (LSCs). This evidence concerns the gene ILK and chronic myelogenous leukemia, BCR-ABL1 positive.